|
Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival
|
07 August 2013 |
|
Novartis delivered growth across all divisions in second quarter
|
22 July 2013 |
|
Novartis and Biological E agree to deliver affordable vaccines for typhoid and paratyphoid A fevers to developing world
|
08 July 2013 |
|
Novartis launches a new campaign to raise awareness of MS
|
29 May 2013 |
|
Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis
|
12 May 2013 |
|
Real-world data at ARVO highlight transformational outcomes seen with Lucentis®
|
08 May 2013 |
|
Novartis delivered solid performance in the first quarter
|
24 April 2013 |
|
Supreme Court denial of Glivec patent clarifies limited intellectual property protection and discourages future innovation in India
|
01 April 2013 |
|
Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
|
21 March 2013 |
|
Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa
|
28 February 2013 |